Device Week, Aug. 29, 2018 – Medtronic’s Uplifting Figures And Data

The medtech industry’s number one player, Medtronic, is the focus of this edition of Device Week, as the firm hit the headlines with some impressive first fiscal quarter results and positive data from a trial of its Synchromed II drug infusion pump. Medtech Insight’s Reed Miller and Tina Tan chat about what helped to boost the company’s top- and bottom-lines and delve deeper into the SISTERS trial for Synchromed and the impact these results will have on the company’s pain management business. For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR Medtech Insight articles addressing topics discussed in this episode: Medtronic's Eyes Are Still Peeled For M&A, But Organic Growth Is The Primary Goal Positive SISTERS Data Could Lift Medtronic's SyncroMed II From Recall Repercussions https://medtech.pharmaintelligence.informa.com/articles/2018/08/21/medtronics-eyes-are-still-peeled-for-ma-but-organic-growth-is-the-primary-goal